Ironwood Pharmaceuticals | IRWD - Beneficio Bruto En Ventas

Precio De Mercado
3.50
Cambio Diario
-0.12 -3.31%
Mensual
-27.69%
Anual
133.33%
Q1 Expectativa
3.32




Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Akebia Therapeutics USD 49.21M 13.25M 2025-03
Almirall EUR 429.87M 180.02M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 22.21M 28.15M 2025-09
Ardelyx USD 106.35M 23.51M 2025-09
Astellas Pharma JPY 456.81B 38.02B 2025-12
AstraZeneca USD 12.39B 5M 2025-12
Charles River Laboratories USD 271.96M 39.43M 2025-12
Coherus Biosciences USD 4.95M 15.34M 2025-03
Esperion Therapeutics USD -29.52M 32.4M 2024-09
Exact Sciences USD 583.93M 21.48M 2025-09
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Incyte USD 1.39B 118.68M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Lexicon Pharmaceuticals USD -16.16M 2.89M 2024-06
MacroGenics USD 61.25M 88.71M 2025-09
Moderna USD 226M 583M 2025-12
Myriad Genetics USD 143.8M 8M 2025-09
Pacira USD 142.25M 11.34M 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12